Introduction
With over one-third of the world's population infected with Mycobacterium tuberculosis and 3 million people killed by the disease per year, tuberculosis (TB) is an emerging global problem. However, in the presence of an effective immune response, only 5-10% of the infected population will develop active TB in their lifetime. The emergence of multidrug-resistant and extensively drug-resistant TB strains coupled with increasing incidence of HIV co-infection threatens to return to an era without any effective way of controlling this disease (1) . After inhalation, the bacteria travel to distal regions of the lung and are engulfed by lung dendritic cells (DC) and macrophages. Despite the recognition that T h 1 immunity is critical in preventing progression to active disease, several aspects on how the innate immune response shapes the adaptive T h 1 immune response, how T h 1 immunity participates in the formation of the tuberculous granuloma and why T h 1 immunity is not sufficient to completely eradicate M. tuberculosis continue to constitute a conundrum (2) . Recent reports suggest a cross-regulation between adrenal steroids (glucocorticoids and dehydroepiandrosterone, DHEA) and the maturation and function of antigen-presenting cells (APCs) (3) (4) (5) . To date, endocrine regulation of DC function is an issue poorly studied; only one report demonstrated an effect of DHEA-sulphate (DHEA-s) on the maturation of DCs where the presence of DHEA-s during maturation of DCs induced an increased ability of DC to stimulate T h 1 cytokine production by T cells in terms of IFN-γ production (5) .
The effects of DHEA are often opposed by the other important adrenal steroid cortisol (6) . The DHEA/cortisol ratio is abnormal during various pathological conditions characterized by immune dysfunction, such as AIDS, rheumatoid arthritis and TB (7) (8) (9) . Specifically in TB, an enhancer effect of DHEA on M. tuberculosis-induced IFN-γ production by PBMC has been demonstrated, together with a reduction in the synthesis of transforming growth factor (TGF)-β, indicating a role for adrenal hormones in the control of TB (10) . Moreover, we recently demonstrated an enhancing role for DHEA in the immune response against M. tuberculosis during HIV-TB co-infection and immune reconstitution inflammatory syndrome (IRIS) (11) .
In this study, we sought to investigate the relevance of the adrenal axis (especially of DHEA) in the modulation of DC function in the context of TB, a disease where the induction of a T h 1 environment by APCs is crucial for the development of an effective immune response to the mycobacteria.
Methods
In vitro differentiation and culture of DC DC were differentiated from PBMC as described earlier (12) . Briefly, PBMC were separated from 15 healthy blood donors using Ficoll Hypaque density gradient and monocytes were purified by Percoll gradients. Monocytes were cultured for 5 days in RPMI 1640 medium supplemented with 1% HEPES 2 mM l-glutamine, 1% streptomycin and penicillin (SigmaAldrich), 10% fetal bovine serum (Natocor), recombinant cytokines IL-4 (15 ng ml −1 ; BD Biosciences) and granulocyte macrophage colony-stimulating factor (30 ng ml −1 ) to obtain immature DCs. Immature DC were stimulated with heat-killed M. tuberculosis (H37Rv, 10 µg ml 
Evaluation of DC phenotype
For the analysis of cell surface antigens, the following mAbs were used: HLA-ABC, HLA-DR, CD1a, CD80, CD86 and CD83 (all from BD Biosciences). Cells were analyzed in a flow cytometer. Cells were acquired in a FACSCanto flow cytometer and analyzed with FACSDiva software (BD Biosciences).
Western blotting
DC were stimulated for 20 min with M. tuberculosis in the presence or absence of DHEA at the indicated concentrations and thereafter cells were washed and solubilized in lysis buffer to prepare whole cell extracts as described (13) . Equivalent amounts of protein were analyzed by 10% SDS-PAGE, transferred to nitrocellulose (Hybond ECL Nitrocellulose Membrane, Amersham Biosciences) and incubated with anti-phospho-ERK, anti-ERK1/2, anti-Iκ-Bα (Santa Cruz Biotechnology) or anti-β-actin (Sigma-Aldrich) antibodies. Bound antibodies were revealed with HRP-conjugated affinity purified anti-mouse antibody (GE Healthcare) or HRPconjugated affinity purified anti-rabbit antibody (Santa Cruz Biotechnology), using enhanced chemiluminescence (ECL, Amersham Biosciences) and Kodak BioMax films.
Assessment of APC function of DCs
The ability of adrenal hormones to modulate M. tuberculosispresenting DCs to stimulate T cells was assessed by using an autologous DC-T-cell co-culture. Briefly, CFSE-stained lymphocytes were plated in 96-well round-bottomed tissue culture plates (2 × 10 5 per well), and DC were added to give different DC:T-cell ratios. Supernatants of DC-T-cell co-cultures were collected on day 4, and IFN-γ levels determined by ELISA. T-cell proliferation was assessed by flow cytometry by CFSE dilution assays at day 6. Also, IFN-γ-producing T lymphocytes were determined by intracellular staining by flow cytometry. As a positive control, cells were stimulated with PHA.
Statistical analysis
Comparisons between groups were done by using non-parametric Kruskal-Wallis and Mann-Whitney tests. Analysis of related samples was performed by the Wilcoxon signed-rank test. Values of P < 0.05 were considered significant.
Results
We investigated the modulation of the functional capacity of M. tuberculosis-activated DCs by adrenal hormones. To achieve this, we initially assessed the cytokine profile (IL-12, IL-10, TNF-α) produced by DCs after inducing their maturation overnight with M. tuberculosis in the presence or absence of cortisol (10 −6 M) or DHEA (10 −7 M) alone or in combination. We observed, as expected, a significant increase on the production of IL-12 (P < 0.05), TNF-α (P < 0.05) and IL-10 (P < 0.0001, Fig. 1 ), after M. tuberculosis stimulation. Addition of cortisol to the cultures significantly inhibited the M. tuberculosis-induced secretion of the three cytokines studied (Fig. 1A-C) . Remarkably, DHEA improved the production of IL-12 in response to M. tuberculosis stimulation (P < 0.05, Fig. 1A ), could not modify TNF-α synthesis (Fig. 1B) and diminished the IL-10 secretion (P < 0.05, Fig. 1C ). We could not observe a reversion of the inhibitory effects induced by cortisol by DHEA treatment (data not shown).
Maturation of DC induced by mycobacteria often involves activation of mitogen-activated protein kinase (MAPK) such as ERK1/2 and nuclear factor (NF)-κB pathways (14, 15) . Within this setting, we observed that M. tuberculosis induced the phosphorylation of ERK1/2 and the degradation of IκBα (Fig. 1D ). The addition of DHEA enhanced the activation of ERK1/2 induced by the antigen and notably, DHEA inhibited the degradation of IκBα, therefore indicating a diminished translocation of NF-κB to the nucleus (Fig. 1D) . Culture of DCs with DHEA alone resulted in no changes in the abovementioned signaling molecules.
Since the expression of antigen-presenting proteins and co-stimulatory molecules are strongly related to DC function (16), we assessed the phenotype of DCs after inducing their maturation overnight with M. tuberculosis in the presence or absence of cortisol or DHEA alone or in combination, Fig. 1E-H, respectively) . Interestingly, the presence of DHEA during the culture period enhanced the M. tuberculosis-induced expression of MHC I (P < 0.05, Fig. 1E ), MHC II (P < 0.05, Fig. 1F ) and CD86 (P < 0.05, Fig. 1G ), without affecting CD83 expression (Fig. 1H) . Cortisol treatment significantly inhibited the abovementioned functions exerted by M. tuberculosis-induced DCs (Fig. 1E-G) and this effect could not be reverted by DHEA addition (data not shown).
Finally, we sought to investigate whether DHEA could affect the ability of DCs to activate antigen-specific T cells. To achieve this, monocyte-derived DC were loaded with M. tuberculosis in the presence or absence of DHEA at different concentrations, and afterward co-cultured in the presence of syngeneic lymphocytes with the aim of assessing M. tuberculosis-specific proliferation and IFN-γ production by T cells. We observed that M. tuberculosis-activated DCs promoted T-cell proliferation, which was enhanced by DHEA ( Fig. 2A and B) . Furthermore, DHEA also increased the production of IFN-γ by activated T cells in response to M. tuberculosis stimulation (Fig. 2C) , and also the frequency of IFN-γ-producing T lymphocytes (depicted in Fig. 2D ).
Discussion
So far, there are no reports describing the effect of adrenal hormones on DC function in the context of TB infection. Several authors demonstrated an effect of cortisol and DHEA on DC maturation and function, showing a decrease in cytokine production, antigen presentation, T-cell co-stimulation and activation among other functions induced by corticosteroids (3, 4, (17) (18) (19) (20) and an enhancement by DHEA of DCs' capacity to induce T-cell allostimulation (3) but not in the framework of an intracellular infection such as TB. Our data indicate that DHEA immune intervention may positively affect DC function since we observed an induction of a pro-inflammatory cytokine milieu, increment on the expression of molecules involved in antigen presentation and T-cell co-stimulation, along with an enhancement on the M. tuberculosis-specific T-cell stimulation by DCs.
Our results show that DHEA increased IL-12 production from M. tuberculosis-stimulated DCs, which may favor the development of T h 1 responses, crucial for the protective immune response to the mycobacteria. In contrast, DHEA treatment was not able to influence TNF-α production, vital to shape microbicidal granulomas and to control M. tuberculosis infection. This result becomes relevant when analyzing the importance of DHEA in the control of latent TB, a condition where the granuloma is a fundamental structure to restrict mycobacterial growth in the lung (21) . In line with these observations, we previously demonstrated an enhancing role for DHEA in the immune response against M. tuberculosis during HIV-TB co-infection and IRIS since DHEA improved T h 1 M. tuberculosis-specific responses in patients dually infected with TB and HIV (11) .
One immune-limiting mechanism during TB is the inhibitory and anti-inflammatory cytokine IL-10. IL-10 is produced by many hematopoietic cells and a major role is to suppress macrophage and DC functions, which are required for the capture, control and initiation of immune responses to pathogens such as M. tuberculosis (22) . Infection by M. tuberculosis induces high levels of IL-10 by DCs (23) . We observed that both DHEA and cortisol diminished IL-10 secretion induced by M. tuberculosis stimulation without altering DC viability (data not shown). These results are in contrast to those published by Toebak et al. (19) , who measured IL-10 production by DCs upon ligation of CD40 observing no changes after hydrocortisone or dexamethasone treatment of monocytederived DCs. On the other hand, it has been shown that DHEA negatively regulates the production of IL-10 during aging (24) and in several murine models (revised in ref. 9 ). We propose a scenario where the cell reaches its maximum after M. tuberculosis stimulation, and the addition of cortisol may weaken the capacity of DCs to secrete IL-10.
Several authors have demonstrated the involvement of the MAPK and NF-κB signaling pathways in M. tuberculosis-induced DC maturation (14, 25, 26) . Our data show that DHEA signaling induces MAPK activation in M. tuberculosisstimulated DCs, therefore contributing to the T h 1 immune responses necessary to eliminate the bacteria. Of note, our demonstration that DHEA at supra-physiological concentrations inhibited IκBα degradation suggests a diminished NF-κB translocation to the nucleus, therefore negatively affecting DC activation. However, previous studies have shown that DHEA-s can inhibit the ability of reactive oxygen species to stimulate degradation of the Iκ-Bα protein (27) . Since different NF-κB subunits exert distinct roles in regulating inflammatory and T-cell stimulatory functions in DCs, where the p50 and cRel NF-κB subunits would regulate genes important for DC-induced T-cell responses (e.g. CD40, IL-12 and IL-18) but not for genes encoding inflammatory cytokines (e.g. TNF-α, IL-1α and IL-6) and the RelA subunit would modulate the expression of inflammatory cytokine genes but not T-cell stimulatory genes (28) , the observed responses modulated by DHEA after M. tuberculosis stimulation may be due to the integration of different signaling pathways rather than the NF-κB signaling pathway alone.
Regarding the surface DC molecules involved in antigen presentation and co-stimulation, we observed that CD86, a well-known activation marker for DCs, was augmented by DHEA, supporting the enhancing role of this adrenal hormone on the functional capacity of DCs in TB. Also, we observed on SDS-PAGE, transferred to a polyvinylidene difluoride membrane and then analyzed by western blotting. The p-ERK and ERK proteins were detected by their specific antibodies. The activation of NF-κB was determined by detecting the degradation of IκBα using a specific antibody. Data are representative of three independent experiments performed with DC from three different donors. that MHC class I and II molecules were up-regulated by DHEA treatment after M. tuberculosis stimulation of DCs, suggesting an impact not only on T h responses but also on CD8 + lymphocytes, possibly influencing both their cytotoxic and cytokine-producing capacities. These observations are in agreement with our results showing an increment on the functional capacities of specific T cells after DHEA treatment of DCs and also with our previous data showing an enhancement of M. tuberculosis-specific immune responses in HIV-TB co-infected individuals (11) . Finally, the expression of CD83, a marker for DC activation, was not modified by DHEA addition, suggesting that this hormone fails to modify the maturation status of DCs in the context of TB infection.
It has been suggested that the development of TB is due to failure of immune regulation or inappropriate immune regulation (29) . The disturbances in immune regulation may speculatively involve the subversion of a protective T h 1 response, including the generation of CD8 + CTL, by several mechanisms including T h 2-like cytokines, TGF-β, Treg or other regulatory cells, and hitherto undescribed mechanisms afflicting the protective T h 1 pathways (30), including DC maturation and differentiation. Thus, a more effective and shorter treatment may require modulation of the immune system and a switch away from an immunopathologic phenotype to a protective one. In this regard, our previous findings suggesting an enhancement of T h 1 responses concomitant with a downmodulation of Treg function by DHEA treatment (11) could set a scenario where treatment of TB could be enhanced by using DHEA as a treatment adjuvant for mycobacterial diseases, especially in the context of HIV infection.
The data presented here show for the first time the relevance of the adrenal axis (especially of DHEA) in the modulation of DC function in the context of TB, a disease where the induction of a T h 1 environment by APCs is crucial for the development of an effective immune response to the mycobacteria. Because of its immune modulatory effects, DHEA supplementation or treatment with DHEA derivatives may be a novel and inexpensive approach to treat conditions where a skewing of the immune response toward an unfavorable cytokine profile may contribute to pathology, as is the case for mycobacterial infections (9) . DHEA has also been proposed as a vaccine adjuvant, since this approach has proved successful, with DHEA administration augmenting the immune response of aged mice to a range of vaccines (9) . While further studies are necessary to get a deeper understanding of the mechanisms involved in DHEA enhancement of anti-TB immune responses, the possibility of using DHEA or DHEA derivatives as potential adjuvant therapy in TB should be considered. 
